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Abstract
Lung inflammation resulting from oxidant/antioxidant imbalance is a common feature of many
lung diseases. In particular, the role of enzymes regulated by the NF-E2-related factor 2 (Nrf2)
transcription factor has recently received increased attention. Among these antioxidant genes, the
glutathione S-transferase mu 1 (GSTM1) has been most extensively characterized since it has a
null polymorphism which is highly prevalent in the population and associated with increased risk
of inflammatory lung diseases. Present evidence suggests that GSTM1 acts through interactions
with other genes and environmental factors, especially air pollutants. Here, we review GSTM1
gene expression and regulation and summarize the findings from epidemiological, clinical, animal
and in vitro studies on the role played by GSTM1 in lung inflammation. We discuss limitations in
the existing knowledge base and future perspectives and evaluate the potential of pharmacologic
and genetic manipulation of the GSTM1 gene to modulate pulmonary inflammatory responses.
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1. Introduction
Chronic inflammation is a feature of many common lung diseases, such as asthma and
chronic obstructive pulmonary disease (COPD) [1,2]. There is now substantial evidence that
oxidative stress plays an important role in the injurious and inflammatory responses central
to many lung diseases. As a part of endogenous metabolism, as well as in response to
challenge by inhaled environmental agents, the lung continuously generates reactive forms
of oxygen, as well as free radical species [3]. Normally, moderate levels of oxidant species
are thought to function as localized, transient and reversible signals to promote cell
proliferation and survival. However, when the balance between oxidants and antioxidants
shifts in favor of the former, from either an excess of oxidants, depletion of antioxidants, or
decreased expression of antioxidant enzymes, oxidative stress occurs. Oxidative stress
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produces not only direct injurious effects in the lung through oxidation of proteins, DNA,
and lipids, but some of these oxidized molecules (electrophils) also activate pro-
inflammatory molecular mechanisms [4–6]. In addition, inflammation itself is an oxidative
process that causes generation of reactive oxygen species (ROS) by activated cells.
Inflammation and oxidative stress are thus intricately linked and a self-perpetuating cycle
can occur when compensatory antioxidant processes are deficient.
The oxidant sources in the lungs include cell-derived endogenous and inhaled oxidants [7–
9]. Lung cells are protected against oxidant challenge by well developed nonenzymatic and
enzymatic antioxidant systems. The nonenzymatic antioxidants are low molecular weight
compounds such as vitamins (vitamins C and E), beta carotene, uric acid, and glutathione
(GSH). The enzymatic antioxidants include superoxide dismutases, catalase, glutathione
peroxidase, heme oxygenase-1, small molecular weight redox proteins, and glutathione S-
transferases (GSTs) [6].
The mammalian GST gene family consists of at least 16 genes assigned to eight protein
enzyme classes based on their substrate specificity, structure, and kinetic behavior: alpha
(GSTA), kappa (GSTK), mu (GSTM), omega (GSTO), pi (GSTP), sigma (GSTS), theta
(GSTT), and zeta (GSTZ) [10–12]. The human GST genes are located on at least seven
chromosomes [11]. They encode three major families of GST enzymes: cytosolic,
mitochondrial, and microsomal proteins, of which the cytosolic GSTs constitute the largest
family [13]. Most GST classes show a high degree of polymorphism and include several
subtypes. Variant GST alleles have been identified within the general population and
correlated with interindividual variations in protein level and enzymatic activity. The most
extensively studied variant GSTs include the GSTM1 and GSTT1 deletion (null) alleles and
the GSTP1 valine allele (Val/Val) [14]. The significance of GSTM1 polymorphism in
human was first recognized in cancer studies demonstrating that individuals carrying the
GSTM1 deletion allele were at increased risk for colon and lung cancers [15,16]. Other
consequences of the genetic polymorphisms include potential differences in tolerance of
toxic agents. To date, the GSTM1 is the most comprehensively studied among all GSTs, and
is suggested to play an important role in the response to oxidative stress [17], particularly in
the lung [18,19].
2. Genetic polymorphisms and function of GSTM1
The GSTM gene class is one of the most highly evolved mammalian GST classes. In mice
there are 7 GSTM genes [13,20]. GSTM1 is the most abundantly expressed among all of the
GST genes in mouse kidney [21]. In humans, five GSTM genes are encoded by a 100-kb
gene cluster on chromosome 1p13.3 arranged as 5′-GSTM4-GSTM2-GSTM1-GSTM5-
GSTM3-3′ and are known to be highly polymorphic [22–24]. The GSTM1 gene contains
four different alleles allowing for several M1 class polymorphisms, designated as
GSTM1*0, GSTM1*A, GSTM1*B and GSTM1*1x2 alleles [25–27]. GSTM1*0 (GSTM1
null allele) is deleted, and homozygotes express no protein [28], while GSTM1*A and
GSTM1*B differ by a single base in exon 7. The products of these latter two genes combine
to form active, homo- and hetero-dimeric, enzymes [11,29–31]. A unique GSTM1 variant
dGSTM1*1x2, containing a duplicated GSTM1 gene was identified among a Saudi Arabian
population [32]. The GSTM1 null allele arose from a recombination event during evolution
between 2 highly homologous regions flanking this locus, resulting in deletion of a 20-kb
segment [23,33]. The prevalence of GSTM1 deletion polymorphisms varies across ethnic
groups, from 18% to 66% (median, 50%), with the exception of Asians, for whom it is
38%–58% [34,35]. The cDNAs encoded by GSTM1 and GSTM2 share a remarkable 99%
sequence identity [36]. The fact that GSTM1 and GSTM2 are physically linked suggests that
the frequent deletion of the GSTM1 locus is caused by unequal crossing-over [22,23].
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Moreover, GSTM1*A and GSTM3*B are in linkage disequilibrium suggesting that in some
cases, links between clinical phenotype and GSTM1 genotypes may reflect polymorphism in
GSTM3 or, indeed other mu class GST genes [11,37]. In addition to genetic polymorphisms,
the tissue distribution of GSTs is subject to great individual variation. Quantitative analysis
of GSTM1 protein in various human tissues revealed that the liver is the richest source of
cytosolic GSTM1. The other sources include testis, lungs, stomach, brain, kidneys, heart,
breast, colon, pituitary, and the lymphocytes [25,38].
The major function of all GSTs has been considered to be the catalysis of the conjugation of
endogenous and xenobiotic electrophiles (e.g. products of oxidative stress, environmental
pollutants, and carcinogens) with GSH, thereby neutralizing their electrophilic sites, and
rendering the products more water-soluble and excretable [39]. GSTs function as homo- and
hetero-dimeric combinations of subunits within a class, but not between classes [38]. Each
subunit with an estimated molecular mass of ~25 kDa contains a catalytically independent
GSH-binding site in the amino-terminal domain and a hydrophobic substrate binding site in
the carboxy-terminal domain [40].
In recent years a great deal of evidence has shown that GSTs, and in particular GSTM1 and
GSTP1, also have several nonenzymatic functions, in which they regulate a number of
cellular processes that contribute to the intrinsic ability of cells to survive genotoxic,
metabolic and oxidative stress [40–42]. The best-characterized of these properties is the
interaction with other functional cellular proteins, such as c-Jun N-terminal kinase (JNK),
tumor necrosis factor receptor associated factor, apoptosis-signal regulating kinase (ASK)
[43,44], protein kinase C (PKC), and tissue transglutaminase, resulting in significant
functional alteration of the binding partners or post-translational modification and functional
alteration of the GST protein itself [45].
3. GSTM1 expression and regulation
The expression level of GSTs has been shown to be a factor that determines the cellular
sensitivity to a broad spectrum of toxic chemicals. However, the regulation of the expression
of the GST gene families is complex, as they exhibit sex-, age-, tissue-, and species-specific
patterns of expression [38,40]. For example, GSTP1, originally isolated from placenta, is
found mainly in brain, lung, and heart; its expression in liver decreases during embryonic
development, becoming very low in adult tissue [46–48]. GSTM1 and GSTT1 are found in
relatively low concentrations in many organs including the lungs [49]. The expression of
GSTM genes in human lung tissue is most intense in the bronchial epithelium, decreasing in
the distal airways [50–52].
GST expression can be induced by a structurally diverse range of xenobiotics and, to date, at
least 100 chemicals have been identified that induce GSTs [53,54]. Many of the GST
inducers are themselves substrates for these enzymes, or are metabolized to compounds that
can serve as GST substrates [38]. These inducers effect transcriptional activation of GST
genes through either the antioxidant-responsive element (ARE) [55], a Barbie box element,
the xenobiotic-responsive element, the GST P enhancer 1, or the glucocorticoid-responsive
element, which may involve interactions with many transcription factors including aryl
hydrocarbon receptor, CCAAT-enhancer binding protein-β, Maf, Nrl, Jun, Fos, hepatic
nuclear factor-1, peroxisome proliferator–activated receptors, and nuclear factor kB (NFkB)
[38,54]. The most significant development in this field has been the recent identification of a
transcriptional factor, NF-E2-related factor 2 (Nrf2) that appears to bind to the ARE
sequences and enhance transcription of GSTs [56–60]. Nrf2 is ubiquitously expressed in a
wide range of tissues and cell types. Under normal conditions, Keap1 anchors the Nrf2
transcription factor within the cytoplasm targeting it for ubiquitination and proteasomal
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degradation. When cells are exposed to chemopreventive agents and oxidative stress, a
signal involving phosphorylation and/or redox modification of critical cysteine residues in
Keap1 inhibits the enzymatic activity of the E3 ubiquitin ligase complex, resulting in
decreased Nrf2 ubiquitination and degradation. As a consequence, free Nrf2 translocates
into the nucleus and in combination with other transcription factors transactivates the AREs/
electrophile response elements of many cytoprotective genes including GSTM1as well as
Nrf2 itself [61]. In addition to transcriptional regulation, GST expression can also be
controlled by posttranscriptional modulation of mRNA stability and protein modification
[38,54]. Posttranslational modification of protein can also affect the GST activity and may,
therefore, represent another mechanism of control. The activity of GSTM enzymes can be
increased by treatment with ROS [38].
4. Association of GSTM1 with lung inflammation
Oxidant/antioxidant imbalance is a hallmark of lung inflammation [62]. Genetic
polymorphisms associated with reduced activity of antioxidant enzymes including GSTs are
therefore relevant to studies of lung inflammatory disease susceptibility. Moreover, the
etiology of inflammatory lung diseases involves a complex interplay between genetic
background and exposure to multiple environmental stimuli [63]. GSTM1 gene has been a
natural candidate in studies of susceptibility to inflammatory airway diseases with
environmental components because of the high prevalence of the null polymorphism and its
role in detoxification [64–68].
4.1 Epidemiological studies
Asthma and chronic obstructive pulmonary disease (COPD) are two common inflammatory
lung diseases the incidence of which is increasing globally [9,69]. The association of
GSTM1 polymorphism with the risk of these two diseases has been widely investigated
[67]. Asthma is a polygenetic or multifactorial illness characterized by chronic airway
inflammation leading to reversible airflow obstruction [70,71]. GSTM1 has been listed as
one of at least 118 genes to date associated with an asthma-related phenotype [72]. Two
common deletion polymorphisms of GSTM1 and GSTT1 genes have been associated with
asthma in children and adults [73–76]. In addition, a single nucleotide polymorphism in
GSTM1 was also associated significantly with asthma in an African American urban
population [77]. In this study, GSTM1 rs412543 C carriers were almost 3 times as likely to
have asthma compared to individuals without the C allele. GSTM1 CCG haplotype was
associated with a 3 fold increase in the odds of asthma. However, a negative association
between the GTSM1 null genotype and asthma phenotypes was also reported [75,78–82]. To
resolve these conflicting results, a meta-analysis of GSTM1 effects has been conducted but
the conclusion did not favor a substantial role of GSTM1 gene by itself in the development
of asthma, likely due to extreme between-study heterogeneity and publication bias [83]. In a
subsequent meta-analysis of antioxidant genes, the same authors concluded that the GSTM1
association with asthma risk needs to consider gene-gene and gene-environment interactions
[66]. The GSTM1 enzyme has overlapping substrate specificities with other GST enzymes,
a deficiency in one isoform may be compensated by another. Thus, it is perhaps not
surprising that children and adults with combined deletion polymorphisms of the GSTM1
and GSTT1 genes were found to be at a higher risk of developing asthma [73–76,84–86]. In
addition, GSTM1 can act as a modifier gene of GSTP1NAD(P)H:quinine oxidoreductase 1
(NQO1), or nitric oxide synthase genes for the risk of childhood asthma [87–92]. Besides
gene-gene interaction, failure to account for environmental exposures might partly explain
not only the heterogeneity of results across studies, but also the overall negative findings.
Strong environmental effects on asthma phenotypes could mask modest genetic effects and,
more importantly, gene-environment interactions could make the effects of GSTM1 gene
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become substantial only in the presence of oxidant exposures and not detectable at a
population level [83].
Diisocyanate-induced occupational asthma is a dramatic example of gene–environment
interactions causing lung inflammation [67]. The asthma risk related to diisocyanate
exposure was associated with the GSTM1 null genotype [93], which also involved the
interaction between GSTM1 null genotype and N-acetyltransferases [94]. The underlying
mechanism might be due to the deficiency of biotransformation of isocyanates and excretion
of metabolic products in the GSTM1 null workers [95]. Aside from occupational exposure,
air pollution has attracted much attention in its contribution to the development of asthma
and asthma exacerbations [96,97]. Environmental tobacco smoke (ETS) or secondhand
smoke, ambient air pollutants, such as ozone and diesel exhaust particles (DEPs), and
endotoxin and/or other pathogen-associated molecular patterns are the ambient exposures
studied most frequently for interactions with GSTM1 polymorphisms in asthma [98–100].
Ozone is a gaseous air pollutant associated with an increased risk of asthma [97,101,102].
Asthmatic children with GSTM1 null and GSTP1 (Val/Val) genotypes appear more
susceptible to developing respiratory symptoms related to ozone exposure [103]. ETS is an
extremely potent oxidant mixture and important in the etiology of childhood asthma [8,98].
In the Children’s Health Study cohort [104], the effects of in utero exposure to maternal
smoking on asthma and wheezing occurrence were largely restricted to children with
GSTM1 null genotype. Among GSTM1 null children, in utero exposure was associated with
increased prevalence of early onset asthma, asthma with current symptoms, persistent
asthma, lifetime history of wheezing, wheezing with exercise, wheezing requiring
medication, and emergency room visits in the past year. Among children with GSTM1
sufficient genotype, in utero exposure was not associated with asthma or wheezing. Others
have shown that children who either had the GSTM1 null genotype or were homozygous for
the GSTP1 (Val/Val) allele had increased risk of asthma at younger ages related to ETS,
with an increased risk for decreased lung function in adolescence [105]. In addition, GSTM1
deficiency was also shown to increase the adverse health effects including asthma and atopy
of in utero and current ETS exposure [106]. In a recent study GSTM1 null genotype itself
was not significantly associated with asthma. However, the GSTM1 null genotype could
modify the association of the NQO1 polymorphism with asthma in children exposed to ETS
[91]. It should be noted that, to date, evidence for gene-air pollution interactions on asthma
have been reported only in children [107,108]. Susceptibility to air pollution in early life
may differ from that in adulthood [109]. For example, a recent study in adults showed no
significant associations of GSTM1 polymorphism with asthma either alone or in
combination with NQO1 SNPs. The lack of consistence with previous analyses could be
related to the heterogeneity of effects in adults compared with children [109]. Intriguingly,
there is emerging evidence that the risk conferred by GSTM1 may be hereditable. The
Children’s Health Study cohort found that children of non-smoking mothers but with
maternal grand-mother who smoked had a two-fold risk of asthma. A further study by the
same group demonstrated that smoking-related effects on LINE1 methylation could be seen
in GSTM1 null children exposed to cigarette smoke [110].
COPD is another major inflammatory lung disease attributable to environmental exposures,
especially cigarette smoking, and genetic susceptibility [69,111–113]. Candidate
susceptibility genes have been selected in terms of putative pathogenesis of COPD such as
the protease-antiprotease imbalance, oxidative stress and antioxidants, and cytokines and
chemokines related to airway inflammation [114]. Most studies on these candidate genes
have not been consistently replicated possibly due to genetic heterogeneity between different
study populations, phenotypic differences, population stratification, multiple statistical
testing, small sample sizes, and random error [111,115,116]. However, longitudinal studies
of decline in lung function, meta-analyses of candidate gene studies, and family-based
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linkage analyses suggest that variants in GSTM1 and other candidate genes are associated
with susceptibility to COPD [114,117–120]. Again, it is likely that GSTM1 acts in an
epistatic fashion. For example, although the polymorphism of GSTM1, GSTT1 or GSTP1
genes was found unlikely to be individually involved in the pathogenesis of COPD in a
Chinese population [121], the combined GSTM1 and GSTT1 null genotype was a
significant risk factor for developing COPD in Chinese smokers [122]. The co-existence of
the GSTM1 null allele with other genetic polymorphisms, such as the microsomal epoxide
hydrolase exon-3 and homozygous GSTP1 (Val/Val) alleles, also plays a significant role in
the development of COPD [118,119,123–125]. In addition, the expression levels of GSTM1
mRNA was significantly decreased in the COPD lung tissues compared with those in non-
COPD tissues, and most of these decreases were significantly correlated with the degree of
airflow limitation and cigarette smoking [126]. In a study on patients with non-small-cell
lung cancer the presence of at least one active allele in GSTM1 gene had a protective effect
against the development of COPD [127].
4.2 Controlled human studies
An earlier study examining the effects of GSTM1 on ozone-induced serum clara cell protein
CC16 (a biomarker of lung injury) release showed that increases in levels of CC16 and
decreases in lung function were more pronounced in subjects with the combined GSTM1
null and NQO1 CC (wild-type) genotype in healthy volunteers [128]. In a controlled ozone
exposure study (0.1 ppm for 2 h), the same group observed that subjects with the combined
GSTM1 null plus NQO1 CC genotype had greater increases in biomarkers of inflammation
and oxidative stress relative to subjects with other genotypes [129]. Our studies with healthy
young adult volunteers also demonstrated that the GSTM1 null genotype is associated with
increased airways neutrophilic inflammation 24 hours after ozone exposure (0.4 ppm for 2
h) [130]. Interestingly, this association between the GSTM1 null genotype and neutrophilic
lung inflammation was not observed in healthy volunteers exposed to 0.06 ppm ozone [131].
In addition, no difference in inflammatory response (sputum neutrophil count) to ozone was
observed between asthmatic patients with or without the combined GSTM1 null and NQO1
wild-type genotypes [132]. These results suggest that exposure conditions and subject health
status can influence the evaluation on the role of GSTM1 in lung inflammation.
In a separate study, we investigated whether the GSTM1 null genotype is a risk factor for
the development of exacerbated inflammatory responses to inhaled endotoxin [133]. It was
shown that GSTM1-null healthy volunteers had significantly elevated neutrophil counts in
their sputum after endotoxin challenge (20,000 endotoxin units). In contrast, GSTM1
sufficient volunteers showed statistically significant, but blunted increases in neutrophils/mg
sputum, suggesting that the GSTM1 null genotype is a risk factor for the increased acute
respiratory inflammatory response to inhaled endotoxin.
Particulate pollution, such as DEPs, is associated with the occurrence of asthma and allergy
[134]. Individuals with the GSTM1 null genotype showed enhanced nasal allergic responses
in the presence of DEPs [100], indicating that GSTM1 could modify the adjuvant effect of
DEPs on allergic inflammation. In addition, GSTM1 has been shown to be an important
cytoprotective factor that reduces allergen-induced airway responses upon exposure to
second hand smoke [135]. It should be noted however, that these studies on DEP and
secondhand smoke only examined nasal responses and the upper airways and further
verification of the results in the lung or lower airways is expected.
4.3 Animal studies
The use of knockout mice with a single disrupted gene, such as GSTM1, is expected to
pinpoint the role of GSTM1 in the pathogenesis of lung inflammation. To date, no studies
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using GSTM1 knockout mice have been reported in this field although GSTM1 knockout
mice have been used for other studies [136,137]. However, in a mouse model of acute lung
injury, the transcription factor Nrf2 was identified as a candidate gene that protected against
oxidant injury via upregulation of antioxidant and phase II enzyme genes including GSTM1
[138]. In another study the DEP-induced DNA adduct formation was enhanced in the lung
of Nrf2 knockout mice [139].
4.4 In vitro studies
The association of GSTM1 with inflammatory responses has not been extensively
investigated in vitro. In a recent study, we showed that knockdown of GSTM1 expression in
a human bronchial epithelial cell line (BEAS-2B) enhances ozone-induced NFκB activation
and interleukin 8 (IL-8) production [140]. This finding was confirmed in primary human
bronchial epithelial cells from healthy subjects with GSTM1-sufficient or -null genotypes.
Another study with human nasal epithelial cells showed that Nrf2 knockdown correlated
with a significant increase in influenza virus entry and replication [141].
5. Possible mechanisms of GSTM1-modulated lung inflammation
The possible mechanisms underlying GSTM1-modulated lung inflammation are largely
unknown. It has been well recognized that oxidants initiate lung inflammation through their
direct and/or indirect activation of stress kinases and redox-sensitive transcription factors,
such as NFκB, leading to increased expression of a battery of distinct pro-inflammatory
mediators [142].
As described previously, GSTM1 detoxifies electrophilic compounds by catalyzing their
conjugation with reduced GSH. It is presumed that intermediate electrophilic metabolites,
arising in the first phase of detoxification, are not metabolized in GSTM1-null asthmatic
patients and are not excreted. These intermediate metabolites may damage cells and generate
oxidative stress, and thereby contribute to the pathogenesis of asthma [85]. In addition to
this well-characterized catalytic activity, recent evidence has suggested that GSTM1 may
control oxidative stress and inflammation through the regulation of intracellular signaling
pathways by its effects on certain small molecules or by protein-protein interactions with
critical kinases [143]. The ligand-binding capacity of GSTM1 results in the negative
regulation of signaling pathways through sequestration of signaling kinases [144]. For
example, GSTM1 can interact with the N-terminal portion of ASK1, inhibiting oxidative
stress-induced ASK1-dependent apoptosis [43]. ASK1 is a mitogen-activated protein kinase
(MAPK) kinase kinase that activates the JNK and p38 pathways leading to cytokine- and
stress-induced apoptosis [42,145]. Under normal conditions, ASK1 exhibits low activity
because of its sequestration by GSTM1. This protein/protein interaction forms a GSTM1/
ASK1 complex, which is dissociated under oxidative stress, leading to the release and
activation of ASK1 [146,147]. Overexpression of GSTM1 has been shown to repress ASK1
activity and ASK1-induced apoptosis [44]. Mitogen-activated protein kinase/extracellular
signal-regulated kinase kinase kinase 1 (MEKK1) is an important component in the stress-
activated protein kinase pathway. GSTM1 has been shown to inhibit MEKK1 activity
induced by cellular stresses through direct binding of MEKK1 [148], leading to suppression
of MEKK1-mediated apoptosis. Recent evidence also showed GSTM1 could facilitate the
addition of glutathione to cysteine residues in target proteins (S-glutathionylation) [149],
regulating lung inflammation [150].
Knockdown of GSTM1 could increase the production of ROS [151], and enhance the
activity of inflammation-related transcription factor NFkB in ozone-exposed human
bronchial epithelial cells, leading to IL-8 upregulation [140]. Interestingly, the interaction
between broccoli consumption and GSTM1 genotype resulted in complex changes to
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transforming growth factor beta 1 and epidermal growth factor signaling pathways
associated with inflammation [152].
6. Clinical implications of GSTM1 manipulation and antioxidant
supplementation
Given the critical role that oxidative stress plays in lung inflammation, induction of
antioxidant enzymes could constitute a powerful potential chemopreventive approach
against initiation and progression of lung inflammation. Sulforaphane is an isothiocyanate
that activates the transcription factor Nrf2. The richest source of sulforaphane is from
cruciferous vegetables and it is the most potent known naturally occurring inducer of the
phase II enzyme genes [153]. It has been shown that sulforaphane significantly augmented
expression of GSTM1 and its enzymatic activity, and sulforaphane pretreatment inhibited
DEP-induced production of pro-inflammatory cytokines by human bronchial epithelial cells
[154]. In animal models, it can reduce inflammation induced by agents such as cigarette
smoke [155]. The induction of GSTM1 by sulforaphane could also block DEP-induced
enhancement of immunoglobulin (Ig) E production in B cells [156]. Promisingly, in a
human study, we showed that dietary sulforaphane safely and effectively induced expression
of Phase II enzymes including GSTM1 in the upper airway of human subjects, suggesting
the potential of enhancement of Phase II enzyme expression as a novel therapeutic strategy
for oxidant induced lung diseases [157].
In either the presence or absence of GSTM1 enzyme, supplementation of antioxidants
remains a therapeutic option to lung inflammation treatment. As the specific substrate of
GSTM1, GSH is the predominant non-protein thiol in the cells and is a key player in the
maintenance of the cellular redox status [158]. However, GSH is not well absorbed across
the gastrointestinal tract [159]. Thus, oral supplementation does not improve glutathione
status, nor reduce markers of oxidative stress in healthy adults, and thus routine
supplementation may not offer health benefits in the absence of disease or oxidative
challenge [160]. In contrast, supplementation of other antioxidants including vitamins C and
E has been shown to have protective effects in asthmatic children with the GSTM1 null
genotype in Mexico City [18].
7. Conclusion and perspectives
In summary, from the overview of epidemiological studies, controlled inhalation studies,
and the limited animal and in vitro studies currently available, GSTM1 appears to play an
important role in the pathogenesis of lung inflammation. The inconsistent epidemiological
results may be, on the one hand, due to limited sample size, ambiguous definition of clinical
and pathological phenotypes, ethnic population grouping, population admixture (diversity),
publication bias and other factors contributing to the large heterogeneity of studies
[66,161,162]. On the other hand, intragenic, gene-environment, and gene-diet interactions
also significantly confounds the evaluation of the association of GSTM1 with lung
inflammation [65]. Thus, the approaches that consider potential interaction between and
among genes, smoke exposure and antioxidant intake are needed to fully characterize the
role of oxidant/antioxidant balance in pathogenesis [163]. In reorganization of the
overlapping substrate specificities, simultaneous determination of all GST genotypes
appears to be a prerequisite for reliable interpretation of the role of the GSTM1 in lung
inflammation [29]. In addition, the role of epigenetic mechanisms needs to be considered
along with gene-environment interactions, since epigenetic changes may have profound
effects on disease susceptibility [1]. The completion of the Human Genome Project, the
HapMap project, technological advances in genotyping and the potential of genome-wide
association analysis has led to a rapid increase in the number of susceptibility candidate
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genes for asthma and other environmentally induced inflammatory pulmonary diseases.
Most of the studies, however, lack information on the mechanisms by which the
polymorphisms could affect individual’s susceptibility to these lung diseases. Confirmation
of the functional consequences of specific genetic polymorphisms ultimately depends on
performing functional studies [1,67]. In this case, GSTM1 knockout mice and lung cells will
provide unique tools for characterization of the role of GSTM1 in lung inflammation.
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• GSTM1 gene expression, function, and regulation are reviewed.
• GSTM1 acts through interactions with other genes and environmental factors.
• Pharmacologic and genetic manipulation of the GSTM1 gene was discussed.
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